This site is intended for Healthcare professionals only.

Paradigm Shift in CVD Control in Diabetic patients proposed NEJM


Paradigm Shift in CVD Control in Diabetic patients proposed  NEJM

Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management can leave patients at risk for heart attack and stroke. But results from four recent randomized clinical trials suggest that using medications that offer glucose control while reducing the risk for cardiovascular disease could improve patient outcomes.

“Strong evidence provided by the four recent trials published within the past 1.5 to 2 years in the New England Journal of Medicine has shown that some of the modern available therapeutic agents that control blood glucose also help reduce the risk for cardiovascular disease,” said Faramarz Ismail-Beigi, MD, PhD, Professor of Medicine at Case Western Reserve University and Endocrinologist at University Hospitals Cleveland Medical Center and Louis Stokes Cleveland VA Medical Center. “Based on this evidence, we propose that we must shift from our previous paradigm with its monocular focus on control of blood glucose and hemoglobin A1c, to one of control of blood glucose plus preventing cardiovascular disease and death from cardiovascular causes.” Hemoglobin A1c is a common test used to determine a patient’s average blood sugar levels over the previous 2-3 months.

Ismail-Beigi helped conduct three of the four clinical trials, and he and his collaborators recently reviewed trial results in the Journal of General Internal Medicine. The trials each tested a blood sugar-lowering medication–pioglitazone, empagliflozin, liraglutide, or semaglutide–but recruited patients with heart disease or stroke. The goal was to determine whether or not the drugs were safe, but in each study, researchers were surprised to find participants with or at risk of type 2 diabetes also experienced cardiovascular improvements.

“For the first time we have seen glucose-lowering medications that can improve cardiovascular outcomes,” Ismail-Beigi said. “It is highly possible that newer agents in these classes of medications, used singly or in combination, will prove to be more efficacious in the management of type 2 diabetes and prevention of cardiovascular disease, even in patients at earlier stages of the disease process.”

Previous studies focused on tight control of blood sugar have not shown major cardiovascular benefits for diabetes patients. “Strict control of blood glucose levels has shown minor, if any, positive effect on prevention of cardiovascular disease,” said Ismail-Beigi. “In fact, a large NIH-funded clinical trial on type 2 diabetes management failed to show that strict control of blood glucose levels had any positive effect on cardiovascular outcomes or mortality, and in fact, may be harmful.”

The new trial results could help address a major dilemma for clinicians looking for ways to control heart disease and reduce mortality, while simultaneously managing blood glucose in patients with type 2 diabetes.

Said Ismail-Beigi, “Our review focuses on the need for a paradigm shift on how we should think about management of type 2 diabetes. I believe it will necessitate a rethinking of goals and approaches by guideline committees. We also hope that the FDA might consider approving new medications for management of type 2 diabetes not only based on their safety profile and their efficacy to control blood glucose, but also whether the medication reduces overall mortality and cardiovascular-related mortality.”

To read the full article click on the link : Faramarz Ismail-Beigi et al, Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials, Journal of General Internal Medicine (2017). DOI: 10.1007/s11606-017-4061-7

The following two tabs change content below.
Anjali Nimesh

Anjali Nimesh

Anjali Nimesh Joined Medical Dialogue as Reporter in 2016. she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Dr. Bhimrao Ambedkar University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
  1. user
    Murar Yeolekar May 10, 2018, 9:24 pm

    The claim requires to be confirmed in different populations , diabetes being heterogeneous in its patterns over the globe. This would also be a major departure from UKPDS onwards maintaining that euglycemia is important in preventing / postponing vascular disease. There appears no role to finer control with insulin / analogues. For country like India , only pioglitazone fits the bill in context of cost , for long term compliance by the patients. Benefits of the fulcrum of antidiabetics , metformin appears underestimated
    Dr ME Yeolekar. , Mumbai